First, to evaluate the immune cell-dependence of S100, 4T1 tumor growth inhibition was evaluated via the antibody blockade of CD4+ T cells (anti-CD4 antibody, αCD4), CD8+ T cells (anti-CD8α antibody, αCD8), NK cells (anti-Asialo-GM1 antibody, αNK), and macrophages (clodronate liposomes, αMacrophage) in the STING agonist S100 monotherapy group (Figure 6A-D). Here, CD8A is linked to neoplasm.